GlassScriptPhysician profile
Scott L Cornella
NPI 1912263427
$536.63
in general payments reported to CMS, 2019-2025
15 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.20 · 2020: $14.03 · 2022: $98.47 · 2023: $116 · 2024: $108 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340 · Education: $21.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.76 |
| Education | $21.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $134.42 | 2019-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $57.92 | 2019-2023 | Entyvio |
| Boston Scientific Corporation | $54.17 | 2023 | Watchman Flx |
| Abbvie INC. | $51.36 | 2022-2024 | |
| Pfizer INC. | $34.70 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $31.45 | 2024 | Dificid |
| Celgene Corporation | $30.95 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.44 | 2025 | Xifaxan |
| Celltrion USA INC. | $21.17 | 2023 | Yuflyma |
| Regeneron Healthcare Solutions, INC. | $18.50 | 2023 | Dupixent |
| Vivus LLC | $18.39 | 2025 | Pancreaze |
| Mallinckrodt Hospital Products INC. | $16.02 | 2025 | Terlivaz |
| Gilead Sciences, INC. | $15.73 | 2025 | |
| Qol Medical, LLC | $15.25 | 2019 | |
| Shionogi INC | $15.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cornella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.